The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014
Open accessAbstract
Importance: The Patient Protection and Affordable Care Act of 2010 brought attention to adverse drug events in national patient safety efforts. Updated, detailed, nationally representative data describing adverse drug events can help focus these efforts. Objective: To describe the characteristics of emergency department (ED) visits for adverse drug events in the United States in 2013-2014 and describe changes in ED visits for adverse drug events since 2005-2006. Design, Setting, and Participants: Active, nationally representative, public health surveillance in 58 EDs located in the United States and participating in the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project. Exposures: Drugs implicated in ED visits. Main Outcomes and Measures: National weighted estimates of ED visits and subsequent hospitalizations for adverse drug events. Results: Based on data from 42 585 cases, an estimated 4.0 (95% CI, 3.1-5.0) ED visits for adverse drug events occurred per 1000 individuals annually in 2013 and 2014 and 27.3% (95% CI, 22.2%-32.4%) of ED visits for adverse drug events resulted in hospitalization. An estimated 34.5% (95% CI, 30.3%-38.8%) of ED visits for adverse drug events occurred among adults aged 65 years or older in 2013-2014 compared with an estimated 25.6% (95% CI, 21.1%-30.0%) in 2005-2006; older adults experienced the highest hospitalization rates (43.6%; 95% CI, 36.6%-50.5%). Anticoagulants, antibiotics, and diabetes agents were implicated in an estimated 46.9% (95% CI, 44.2%-49.7%) of ED visits for adverse drug events, which included clinically significant adverse events, such as hemorrhage (anticoagulants), moderate to severe allergic reactions (antibiotics), and hypoglycemia with moderate to severe neurological effects (diabetes agents). Since 2005-2006, the proportions of ED visits for adverse drug events from anticoagulants and diabetes agents have increased, whereas the proportion from antibiotics has decreased. Among children aged 5 years or younger, antibiotics were the most common drug class implicated (56.4%; 95% CI, 51.8%-61.0%). Among children and adolescents aged 6 to 19 years, antibiotics also were the most common drug class implicated (31.8%; 95% CI, 28.7%-34.9%) in ED visits for adverse drug events, followed by antipsychotics (4.5%; 95% CI, 3.3%-5.6%). Among older adults (aged ≥65 years), 3 drug classes (anticoagulants, diabetes agents, and opioid analgesics) were implicated in an estimated 59.9% (95% CI, 56.8%-62.9%) of ED visits for adverse drug events; 4 anticoagulants (warfarin, rivaroxaban, dabigatran, and enoxaparin) and 5 diabetes agents (insulin and 4 oral agents) were among the 15 most common drugs implicated. Medications to always avoid in older adults according to Beers criteria were implicated in 1.8% (95% CI, 1.5%-2.1%) of ED visits for adverse drug events. Conclusions and Relevance: The prevalence of emergency department visits for adverse drug events in the United States was estimated to be 4 per 1000 individuals in 2013 and 2014. The most common drug classes implicated were anticoagulants, antibiotics, diabetes agents, and opioid analgesics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13702 · Cited by 2,609
Increases in drug and opioid overdose deaths — United States, 2000–2014
Rudd, R. A., Aleshire, N., Zibbell, J. E., & Gladden, R. M. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6450a3 · Cited by 1,859
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
National Surveillance of Emergency Department Visits for Outpatient Adverse Drug Events
Budnitz, D. S., Pollock, D. A., Weidenbach, K. N., Mendelsohn, A. B., Schroeder, T. J., & Annest, J. L. (2006) · JAMA · doi:10.1001/jama.296.15.1858 · Cited by 893
Self-citationPreventing Medication Errors: Quality Chasm Series
(2007) · doi:10.17226/11623 · Cited by 829
Clarifying Adverse Drug Events: A Clinician's Guide to Terminology, Documentation, and Reporting
Nebeker, J. R., Barach, P., & Samore, M. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-10-200405180-00009 · Cited by 803
Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults
Budnitz, D. S., Shehab, N., Kegler, S. R., & Richards, C. L. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-11-200712040-00006 · Cited by 607
Self-citationNational trends in ambulatory oral anticoagulant use
Barnes, G. D., Lucas, E., Alexander, G. C., & Goldberger, Z. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.044 · Cited by 598
Emergency Department Visits for Antibiotic‐Associated Adverse Events
Shehab, N., Patel, P. R., Srinivasan, A., & Budnitz, D. S. (2008) · Clinical Infectious Diseases · doi:10.1086/591126 · Cited by 535
Self-citationOlfson, M., Blanco, C., Liu, S.-M., Wang, S., & Correll, C. U. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.647 · Cited by 352
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes
Lipska, K. J., Krumholz, H., Soones, T., & Lee, S. J. (2016) · JAMA · doi:10.1001/jama.2016.0299 · Cited by 309
Munshi, M. N., Florez, H., Huang, E. S., Kalyani, R. R., Mupanomunda, M., Pandya, N., Swift, C. S., Taveira, T. H., & Haas, L. B. (2016) · Diabetes Care · doi:10.2337/dc15-2512 · Cited by 243
Carton, L., Cottencin, O., Lapeyre-Mestre, M., Geoffroy, P., Favre, J., Simon, N., Bordet, R., & Rolland, B. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150619092903 · Cited by 204
Jirón, M., Pate, V., Hanson, L. C., Lund, J. L., Funk, M. J., & Stürmer, T. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14077 · Cited by 124
Hohl, C. M., Zed, P. J., Brubacher, J. R., Abu‐Laban, R. B., Loewen, P. S., & Purssell, R. A. (2009) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2009.10.008 · Cited by 97
Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants
Barnes, G. D., Nallamothu, B. K., Sales, A. E., & Froehlich, J. B. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002366 · Cited by 93
Hohl, C. M., Robitaille, C., Lord, V., Dankoff, J., Colacone, A., Pham, L., Bérard, A., Pépin, J., & Afilalo, M. (2005) · Academic Emergency Medicine · doi:10.1197/j.aem.2004.08.056 · Cited by 84
Antipsychotic Medication Prescribing in Children Enrolled in Medicaid
Rettew, D. C., Greenblatt, J., Kamon, J. L., Neal, D., Harder, V. S., Wasserman, R. C., Berry, P., MacLean, C. D., Hogue, N., & McMains, W. (2015) · PEDIATRICS · doi:10.1542/peds.2014-2260 · Cited by 66
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s013 · Cited by 58
Linder, J. A. (2008) · Clinical Infectious Diseases · doi:10.1086/591149 · Cited by 56
National trends in prescription drug expenditures and projections for 2015
Schumock, G. T., Li, E. C., Suda, K. J., Wiest, M. D., Stubbings, J., Matusiak, L. M., Hunkler, R. J., & Vermeulen, L. C. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140849 · Cited by 38
Nutescu, E. A., Bathija, S., Sharp, L. K., Gerber, B. S., Schumock, G. T., & Fitzgibbon, M. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.1161 · Cited by 29
Trends in the use of prescription antibiotics: NHANES 1999–2012
Frenk, S. M., Kit, B. K., Lukacs, S. L., Hicks, L. A., & Gu, Q. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv319 · Cited by 26
Cited by
Wilson, J. E., Mart, M. F., Cunningham, C., Shehabi, Y., Girard, T. D., MacLullich, A. M. J., Slooter, A. J. C., & Ely, E. W. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00223-4 · Cited by 1,200
Advances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
Evaluation and Management of Penicillin Allergy: A Review
Shenoy, E. S., Macy, E., Rowe, T., & Blumenthal, K. G. (2019) · JAMA · doi:10.1001/jama.2018.19283 · Cited by 830
Health, United States, 2007--With Chartbook on Trends in the Health of Americans: (407202008-001)
(2007) · PsycEXTRA Dataset · doi:10.1037/e407202008-001 · Cited by 569
The silent epidemic of chronic pain in older adults
Domenichiello, A. F., & Ramsden, C. E. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.04.006 · Cited by 434
Metadata
- Authors
- Shehab, N., Lovegrove, M. C., Geller, A. I., Rose, K. O., Weidle, N. J., & Budnitz, D. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-11-22
- Volume
- 316
- Issue
- 20
- Pages
- 2115
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2551817902
- Cited by
- 655
- References
- 23
- FWCI
- 111.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.